<DOC>
	<DOCNO>NCT00396149</DOCNO>
	<brief_summary>To investigate safety tolerability successive single rise dos SLIT subject allergic rhinitis investigate safety tolerability multi high dose regimen SLIT subject allergic rhinitis .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacodynamic Effects Sublingual Immunotherapy ( Tablets ) With Recombinant Bet v1</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>write consent Symptoms birch pollen induce allergic rhinitis least last 2 year . Sensitisation birch pollen demonstrate positive SPT birch pollen specific IgE level ( birch pollen r Bet v1 ) least Class 2 screening . FEV1 least 80 % predict value screen . Patient previously receive desensitization treatment birch pollen and/or betulaceae ( e.g. , hazel tree , alderâ€¦ ) plan start desensitization treatment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>rBet v 1</keyword>
	<keyword>Birch pollen allergy</keyword>
	<keyword>Sublingual Immunotherapy</keyword>
</DOC>